Bicara Therapeutics (BCAX) Return on Capital Employed (2024 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Return on Capital Employed of 38.43% for Q1 2026, down 1552.0% year-over-year from 2.65% in Q1 2025, and up 1.49% quarter-over-quarter from 39.01% in Q4 2025.
Bicara Therapeutics (BCAX) Return on Capital Employed (2024 - 2026) Analysis & Trends
Bicara Therapeutics' Return on Capital Employed history runs 3 years deep, the most recent figure standing at 38.43% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1552.0% year-over-year to 38.43%; the TTM figure through Mar 2026 stood at 38.43% (down 1552.0% YoY), while the FY2025 annual figure was 35.24%, down 1197.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 38.43%, up from 39.01% in the prior quarter.
- The five-year high for Return on Capital Employed was 16.51% in Q4 2024, with the low at 39.01% in Q4 2025.
- The 3-year median for Return on Capital Employed is 30.37% (2025), against an average of 29.6%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 2250 bps in 2025, then sank 1552 bps in 2026.
- Bicara Therapeutics' Return on Capital Employed stood at 16.51% in 2024, then sank by 136 bps to 39.01% in 2025, then increased by 1 bps to 38.43% in 2026.
- Business Quant data shows BCAX's Return on Capital Employed at 38.43% in Q1 2026, 39.01% in Q4 2025, and 33.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -41.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.27% |
| Mar 31, 2026 | -38.43% |
| Dec 31, 2025 | -39.01% |
| Sep 30, 2025 | -33.75% |
| Jun 30, 2025 | -26.99% |
| Mar 31, 2025 | -22.91% |
| Dec 31, 2024 | -16.51% |